GRM5 and nervous system disorder: The special active compounds (Arctiin, Corymbosin, and Aloe-emodin) of LHQW target neurological disease-related genes (GRM1 and GRM5), and the special active compounds (isofucosterol, baicalein, nobiletin, oroxylin A, epiberberine, and piperlonguminine) of QFPD target immunity- and inflammation-related genes (mTOR and PLA2G4A).